Capsugel Belgium NV

I'll research this company before writing the profile.

Let me check the litigation case and current ownership status.

Company overview. Capsugel Belgium NV (commonly "Capsugel Belgium") is a Belgian company registered at Rijksweg 11, 2880 Bornem, Belgium; earlier filings list it as Capsugel Belgium BVBA. Third-party databases (PatSnap) give a founding date of 1 October 1961 and describe it as a subsidiary. It is the Belgian operating entity of the Capsugel group, which KKR bought from Pfizer in 2011 and Switzerland's Lonza Group AG (SIX: LONN) acquired in July 2017 for USD 5.5 billion. Capsugel then reported ~3,600 employees across 13 facilities and roughly USD 1 billion in annual sales. In March 2026 Lonza agreed to sell its Capsules & Health Ingredients (CHI) division — which contains the Capsugel business, ~CHF 1.1 billion of 2025 sales — to Lone Star Funds, closing in H2 2026 with Lonza retaining a 40% stake.

Products / services. An operating manufacturer, not a shell. Capsugel Belgium's certified Bornem site manufactures and prints hard gelatin and non-gelatin (HPMC) capsules for pharmaceutical use and distributes all capsule types. Group-wide offerings include vegetarian and enteric capsules (Vcaps, Vcaps Plus, Vcaps Enteric), dry-powder-inhalation capsules (Zephyr), dosage-form solutions such as liquid-filled and multi-compartment capsules, and capsule filling/sealing equipment.

Patent-litigation posture. The tracked data show one case, as plaintiff and none as defendant: Capsugel Belgium NV v. INNERCAP Technologies, Inc., IPR2013-00331, filed 6 June 2013 at the PTAB. This is a patent owner-affiliated operating company petitioning to cancel a competitor's patent at the USPTO, not an NPE campaign, and it is not an Eastern District of Texas assertion. The zero defendant count indicates no tracked patent suits against it in this dataset.

Notable context. IPR2013-00331 targeted Innercap's multi-phase, multi-compartment capsule patents (e.g., US 7,670,612) on public-accessibility/obviousness grounds; the Board's December 2013 decision (Paper 9) is cited in later PTAB cases. Separately, Capsugel patents (US 6,887,307, pullulan film compositions) were themselves challenged at the PTAB by Bright Pharma Caps (IPR2015-01625) — context not reflected in the tracked counts above.